Advanced in Scleroderma

Yukie L. Yamaguchi

Yokohama, JP 
Advanced in Scleroderma
Yokohama, JP 
OverviewLocationsClinical Research

Overview

Yukie Yamaguchi practices in Yokohama, Japan. Ms. Yamaguchi is rated as an Advanced expert by MediFind in the treatment of Scleroderma. Her top areas of expertise are Stevens-Johnson Syndrome, Erythema Multiforme, Scalded Skin Syndrome, and Psoriasis.

Her clinical research consists of co-authoring 386 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 13 articles in the study of Scleroderma.

Gender
Female

Locations

Yokohama, Japan
Other Locations
Tsukuba, Japan
Naka, 3191195, Japan
Tokyo, Japan
Saga, Japan
Okumura, Japan
Minato, 1088641, Japan
Fujisawa, 2520880, Japan
Shinjuku, 1628640, Japan
Toyonaka, 5608531, Japan
Wako, 3510198, Japan
Nisshin, Japan
Kyoto, 6068501, Japan
Nagoya, Japan
Osaka, Japan
Kumamoto, Japan
Saitama, 3510198, Japan
Suita, 5650871, Japan
Higashi, 8128582, Japan
Hongo, 1130033, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Enrollment Status: Completed
Publish Date: September 25, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

386 Total Publications

Prospective, Open-Label, Multicenter Study of Apremilast as Maintenance Therapy for Psoriasis Patients in Remission With Biologics.
Prospective, Open-Label, Multicenter Study of Apremilast as Maintenance Therapy for Psoriasis Patients in Remission With Biologics.
Journal: The Journal of dermatology
Published: August 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Yamaguchi's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile